Welcome to EpilepsyU.com a social network dedicated to the epilepsy community

CBD

Epilepsy Epilepsy expert discusses latest research, side effects and FDA guidance for use aproved CBD treatment

Treating epilepsy presents a variety of challenges for patients and their families. Sometimes, it takes time to find the right medication and dosing to properly manage seizures and other epilepsy-related health issues. Or it may be necessary to adjust the medication so that it doesn’t cause side effects that impact quality of life. This is especially true for patients with two rare forms of severe childhood-onset epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. In the search for new treatments for these rare forms of epilepsy, researchers have been studying marijuana-based drugs for their potential seizure-controlling benefits. In June, the FDA approved cannabidiol (CBD), a marijuana-based medication, for the treatment of seizures in patients (age 2 and older) who have been diagnosed...

Federal chokehold on marijuana stymies studies on epilepsy, autism

A few years ago, I began to see children in my practice who seemingly responded to marijuana-derived extracts. And as a result, I grew cautiously optimistic that these extracts might be good treatments for the condition. As a devout believer in evidence-based medicine, I still needed experimental data that could distinguish bona fide effectiveness from a deceptive impression of benefit — a placebo effect. But my desire to study marijuana ran headlong into a seemingly immovable obstacle: the U.S. Drug Enforcement Agency (DEA). The agency’s illogical and stubborn stance makes it all but impossible for scientists to study cannabidiol. I persevered and eventually succeeded in launching a study, but no doubt many others give up, robbing us of valuable insight into marijuana’s potential benefits...

FDA warns drug manufacturer marketing CBD products

PLEASE BEWARE – DON’T SELF MEDICATE WITH OVER THE COUNTER CBD PRODUCTS/CLAIMS – EpilepsyU The July 31 warning letter reflects FDA’s continuing concern over the marketing of CBD products—including supplements—to treat diseases like cancer and schizophrenia without agency drug approval. For the fourth year in a row, FDA delivered at least one warning letter related to the sale of cannabidiol (CBD), reflecting the agency’s concerns that the cannabis-based compound features claims documenting an intent to treat diseases such as cancer and schizophrenia without necessary drug approval. FDA also reiterated its position that CBD cannot be lawfully sold as a dietary supplement because, in part, it has been subject to substantial clinical investigations held by GW Pharmaceut...

Medical cannabis ‘safe’ for severe childhood epilepsy

Australian Study Shows – A small but significant group had a notable reduction in their seizures lmost all of the first 40 children given cannabidiol for severe epilepsy in Australia had an adverse event within three months — although most were mild and unrelated to the therapy, according to a study. Although four children withdrew from the NSW study, more than half of the cohort showed at least some improvement in the eyes of their treating doctors and carers, say the authors of the paper published in the Medical Journal of Australia. Paediatric neurologists tracked tolerability, adverse events and the subjective impressions of caregivers and treating neurologists among the first group of children with drug-resistant epilepsy and uncountable daily seizures enrolled in the ongoing NS...

Girl who takes medical cannabis to treat seizures attends her first day of kindergarten but school not sure she can have it there!

Sad a school is in the way.  EpilepsyU Santa Rosa family fights for girl’s medical cannabis use in school “A Santa Rosa girl who relies on cannabis-based oil to treat a rare form of epilepsy started kindergarten Monday under a court order that allows her to attend class while a judge decides whether the Rincon Valley Union School District can ban the medication from school grounds. Brooke Adams, 5, has Dravet syndrome, a lifelong disorder that causes frequent and prolonged seizures. Her family treats the genetic disease using daily doses of THC oil and cannabidiol, a marijuana compound also known as CBD. Brooke must carry the oil with her at all times because larger doses of the medication, which is applied to her gums, stops the seizures when they strike, mother Jana Adams sai...

CBDs Enabling Improvements In Treatment Resistant Epilepsy

Evidence has been just been released revealing that CBD oils can significantly improve seizure frequency, symptoms and other measures of efficacy in patients suffering with treatment resistant epilepsy, as published in the journal Epilepsy and Behavior. Results of this study from researchers at the University of Alabama indicate use of CBD oil reduced adverse events and seizure severity along with decreases in overall seizure frequency. 132 patients were included in this study: 60 adults and 72 children with intractable epilepsy who did not respond to traditional therapies. Subject data was analyzed at baseline and again from visits at 12, 24, and 48 weeks. Frequency of seizures decreased from mean of 144 seizures every 2 weeks at baseline to 52 seizures over 2 weeks, decreases remained st...

GW Pharma Reveals Epidiolex Pricing

GW Pharmaceutical released financials for its fiscal 2018 Q3 after the close today and hosted a conference call for investors and analysts. Readers can access a full transcript provided courtesy of Seeking Alpha. As the company nears the launch of its cannabis-derived treatment for seizures in patients with rare forms of epilepsy, the investor community is focused almost exclusively on Epidiolex and its commercialization. One of the big questions for the company in recent quarters has been its expected pricing, and the company revealed during the conference call for the first time that Epidiolex will cost $32,500 per year on average, depending upon the weight of the patient and the dosing. The goal of the company, according to Julian Gangolli, who, as President, North America, is leading t...

Australian Study Shows That Even Low CBD Extracts Can Treat Epileptic Seizures

It’s been widely believed that CBD is the compound in cannabis with medicinal value, but a new study out of Australia shows that THC shouldn’t be discounted in medical use either. The study, out of the University of Sydney, looked at parents who turned to medicinal cannabis to treat epileptic seizures in their children, many of who were getting their drugs through the black market.

Medical cannabis for epilepsy approved in FDA first

In the context of an ever-louder international debate on whether patients with severe forms of epilepsy should be allowed to use medical cannabis to manage their condition, the Food and Drug Administration have just officially approved one such drug.   The Food and Drug Administration have just approved a cannabis-based drug for the first time.  

The FDA Says It Will Likely Never Approve Smoking Cannabis

The federal agency joins a community of health experts who think smoking is not a good way to consume weed.   The commissioner of the Food and Drug Administration, Scott Gottlieb, recently suggested that the agency would never approve of smoking cannabis. This opposition to smoking is shared by many health experts, even those who approve of medical cannabis in general. FEATURED PHOTO: WASHINGTON, D.C. – APRIL 05: FDA Commissioner-designate Scott Gottlieb testifies during a Senate Health, Education, Labor and Pensions Committee hearing on April 5, 2017 on Capitol Hill in Washington, D.C. (Photo by Zach Gibson/Getty Images)

Cannabis Compound Confirmed as Epilepsy Treatment for Atonic Seizures (Drop Attacks)

Cannabidiol (CBD), a compound derived from the cannabis plant that does not produce a “high” and has been an increasing focus of medical research, was shown in a new large-scale, randomized, controlled trial to significantly reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.   In the new study comparing 2 doses of CBD to a placebo, the researchers reported a 41.9 percent reduction in “drop seizures”—a type of seizure that results in severe loss of muscle control and balance—in patients taking a 20 mg/kg/d CBD regimen, a 37.2 percent reduction in those on a 10 mg/kg/d CBD regimen, and a 17.2 percent reduction in a group given a placebo.

Epilepsy, Medical Marijuana and CBD: Myths and Facts

While a Food and Drug Administration advisory panel recently recommended pharmaceutical-grade cannabidiol (CBD) as a treatment for two rare forms of epilepsy, CBD medication is not the same thing as medical marijuana, which is more available than ever before and promoted for wide variety of health conditions. The American Epilepsy Society (AES) wants to alert the 3 million people with epilepsy about the myths and facts related to CBD medication – derived from one of the many compounds found in in cannabis (the marijuana plant) – and medical marijuana.   Medical marijuana, which is now legal in 29 states as well as the District of Columbia, refers to the physician-prescribed use of the whole, unprocessed marijuana plant or its basic extracts to treat the symptoms of an illness and othe...

  • 1
  • 2
  • 5